checkAd

    TG Therapeutics TGTX (Seite 2)

    eröffnet am 13.07.20 10:32:08 von
    neuester Beitrag 06.05.24 23:08:41 von
    Beiträge: 470
    ID: 1.327.694
    Aufrufe heute: 2
    Gesamt: 38.054
    Aktive User: 0


    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 2
    • 47

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 10.01.24 17:12:28
      Beitrag Nr. 460 ()
      Antwort auf Beitrag Nr.: 75.080.370 von questionmark am 10.01.24 16:50:02Übertrieben , wird sich wieder erholen
      TG Therapeutics | 17,44 $
      Avatar
      schrieb am 10.01.24 16:50:02
      Beitrag Nr. 459 ()
      kommt nicht so gut an, mal sehen, wo das heute endet
      TG Therapeutics | 17,94 $
      1 Antwort
      Avatar
      schrieb am 10.01.24 13:08:58
      Beitrag Nr. 458 ()
      https://ir.tgtherapeutics.com/news-releases/news-release-det…


      TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
      Jan 10, 2024


      Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively

      Preliminary year-end 2023 cash position of approximately $215 million




      NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023 (unaudited), as well as financial guidance and development milestones for 2024, during a preannounced presentation at the 42nd Annual J.P Morgan Healthcare Conference. An audio replay of the event, as well as the corresponding slide deck are available on the Investors and Media section of the TG corporate website at ir.tgtherapeutics.com/events.

      Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share our preliminary fourth quarter and year end U.S. BRIUMVI net product revenue. As we head into 2024, we have our sights set on achieving revenue and expense targets and have built an ambitious plan to potentially expand the utility of BRIUMVI into new indications and for use as a subcutaneous injection. We are also excited to expand our R&D program with the recent licensing of azer-cel, an allogeneic CD19 CAR T therapy which we believe has the potential to become a meaningful therapy to treat various autoimmune disorders.”

      Preliminary Fourth Quarter and Full Year 2023 Updates (based on unaudited financial information)

      BRIUMVI U.S. net product revenue expected to be approximately $40 million and $89 million for the fourth quarter and full year of 2023, respectively
      Year-end 2023 cash position of approximately $215 million
      Preliminary selected financial information presented in this release are unaudited, subject to financial closing procedures and adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results planned to occur February 2024.

      2024 Target Guidance

      BRIUMVI U.S. net product revenue targets of approximately $41-$46 million and $220-$260 million for the first quarter and full year 2024, respectively
      Full year 2024 target operating expense of approximately $250 million
      2024 Development Pipeline Anticipated Milestones

      Commence clinical development of subcutaneous BRIUMVI
      Commence a trial evaluating BRIUMVI in additional autoimmune diseases outside of Multiple Sclerosis (MS)
      Commence a trial evaluating azer-cel in autoimmune disease
      Present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences throughout the year
      TG Therapeutics | 21,00 €
      Avatar
      schrieb am 06.12.23 16:59:54
      Beitrag Nr. 457 ()
      Zitat von questionmark: entwickelt sich prächtig, ohne relevante news, oder hab ich etwas verpasst?


      die Darmstädter Merck KGaA hat bei nem pot. Konkurrenz-Produkt verkackt... Studie wurde eingestellt, ein weiterer Konkurrent weniger für die Zukunft 🔥
      TG Therapeutics | 16,44 $
      Avatar
      schrieb am 06.12.23 16:09:34
      Beitrag Nr. 456 ()
      entwickelt sich prächtig, ohne relevante news, oder hab ich etwas verpasst?
      TG Therapeutics | 16,14 $

      Trading Spotlight

      Anzeige
      JanOne
      3,9700EUR +3,66 %
      Heftige Kursexplosion am Montag?!mehr zur Aktie »
      Avatar
      schrieb am 01.11.23 14:01:04
      Beitrag Nr. 455 ()
      TG Therapeutics | 8,936 €
      Avatar
      schrieb am 14.08.23 18:13:50
      Beitrag Nr. 454 ()
      na, dann bleib ich doch erst mal dabei, 100 k stücke hat er sich gegönnt
      TG Therapeutics | 10,91 $
      Avatar
      schrieb am 14.08.23 17:07:22
      Beitrag Nr. 453 ()
      TG Therapeutics | 10,69 $
      Avatar
      schrieb am 03.08.23 20:14:03
      Beitrag Nr. 452 ()
      Ich hab wieder verkauft. Erst möchte ich Verkaufserfolge sehen, bevor ich hier wieder ernsthaft investiere.
      TG Therapeutics | 11,71 $
      Avatar
      schrieb am 03.08.23 18:29:14
      Beitrag Nr. 451 ()
      So, zweite tranche gekauft
      TG Therapeutics | 11,19 $
      • 2
      • 47
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      +0,44
      -0,74
      +0,04
      -1,14
      -0,43
      +2,72
      +0,72
      -0,34
      -2,85
      0,00

      Meistdiskutiert

      WertpapierBeiträge
      48
      44
      26
      21
      17
      17
      13
      12
      10
      10
      01.05.24 · globenewswire · TG Therapeutics
      30.04.24 · globenewswire · TG Therapeutics
      18.04.24 · globenewswire · TG Therapeutics
      18.04.24 · globenewswire · TG Therapeutics
      15.04.24 · globenewswire · TG Therapeutics
      08.03.24 · globenewswire · TG Therapeutics
      01.03.24 · globenewswire · TG Therapeutics
      28.02.24 · globenewswire · TG Therapeutics
      27.02.24 · globenewswire · TG Therapeutics
      26.02.24 · globenewswire · TG Therapeutics
      TG Therapeutics TGTX